Diversification is essential for the generation of immune protection 1 . Bone marrow B cell precursors generate antigen-recognition diversity by recombining variable (V), diversity (D) and joining (J) exons encoding antigen-binding immunoglobulin heavy (H)-and light (L)-chain V regions (V H DJ H and V L J L ) from individual V, D and J gene segments 2 . The mature B cells that emerge from the bone marrow further diversify their immunoglobulin gene repertoire through somatic hypermutation and class-switch recombination (CSR) of DNA. Somatic hypermutation introduces point mutations at high rates into recombined V H DJ H and V L J L exons, thereby providing a structural correlate for the selection of immunoglobulin variants with higher affinity by antigen, whereas CSR endows immunoglobulin molecules with new effector functions by replacing the heavy-chain constant region (C H ) of immunoglobulin M (IgM) with that of IgG, IgA or IgE without changing antigen specificity 3 .
A r t i c l e s the interaction of CD40L on CD4 + T cells with CD40 on B cells 6 . The ensuing oligomerization of CD40 (A000031) triggers recruitment of the TRAF TNF receptor-associated adaptor proteins to its cytoplasmic domain 7 . These TRAF proteins activate an IκB kinase (IKK) complex composed of two αand β-catalytic subunits and a γ-regulatory subunit 8 . By phosphorylating the transcription factor NF-κB inhibitor IκBα (A000097), which retains NF-κB an inactive cytoplasmic state under resting conditions, IKK elicits ubiquitination and proteasomedependent degradation of IκBα, thereby allowing nuclear translocation of NF-κB 8 . In the presence of cytokine-induced transcription factor STAT proteins, CD40-induced NF-κB initiates the transcription of targeted C H genes as well as of AICDA, which encodes AID 3 .
CD40 signaling leads to the induction of class-switched and hypermutated memory B cells as well as immunoglobulin-secreting plasma cells from follicular B cells, which provide long-term protection 9 . This T cell-dependent pathway takes 5-7 d, a period too long for the control of rapidly replicating pathogens 10 . As a means of overcoming this limitation, extrafollicular B cells produce IgM, IgG and IgA through a faster T cell-independent pathway involving BAFF and APRIL [11] [12] [13] [14] [15] . These factors are released by cells of the innate immune system in response to microbial signals emanating from Toll-like receptors (TLRs) and activate NF-κB by recruiting TRAF proteins through the transmembrane activator TACI (A002248) and two receptors related to TACI: B cell-maturation antigen (BCMA) and BAFF receptor (BAFF-R; also called BR3) 16 . Of these receptors, TACI mediates CSR, at least in mouse B cells 15, 17, 18 .
Deleterious mutations of the gene encoding TACI are common in human populations, particularly in patients with common variable immunodeficiency (CVID), a disorder in which the production of IgG, IgA and IgM is impaired [19] [20] [21] [22] . The mechanism by which TACI triggers CSR remains unknown, but published findings raise the possibility that BAFF-induced production of IgG involves a T cellindependent pathway composed of MyD88 (A003535) 23 . This adaptor protein regulates innate immunity by activating NF-κB and other transcription factors through the Toll-interleukin 1 (IL-1) receptor (TIR) domain of TLRs and IL-1 receptor (IL-1R) 24 .
We show here that BAFF and APRIL promoted recruitment of MyD88 to a conserved cytoplasmic motif of TACI distinct from the TIR domain of TLRs. The TACI-MyD88 interaction induced CSR by triggering NF-κB activation, germline C H gene transcription and AICDA expression through a TIR-independent pathway that was impaired in mice and humans lacking MyD88 or the IL-1R-associated kinase IRAK4, a signal transducer that binds MyD88 (ref. 24) . Thus, we propose that MyD88 enhances immunoglobulin diversification and production by linking the innate and adaptive immune systems through TACI.
RESULTS

TACI signals CSR in cooperation with TLRs
Patients with mutations in the gene encoding TACI produce less IgG and IgA 19, 20, 22, 25 . We investigated the function of human TACI in more detail by visualizing TACI expression in lymphoid organs from healthy subjects through immunohistochemistry. Follicular B cells, which usually mediate T cell-dependent (CD40-dependent) immunoglobulin responses, had higher TACI expression in IgD − germinal centers than in the IgD hi mantle zone (Fig. 1a) . Extrafollicular IgD lo B cells, which mediate T cell-independent (CD40-independent) immunoglobulin responses, had higher TACI expression than did follicular mantle IgD hi B cells. TACI was particularly abundant in IgD lo B cells from the subepithelial area of the tonsils and the marginal zone of the spleen.
After our detection of TACI on extrafollicular B cells, we reasoned that TACI might initiate CD40-independent CSR. We tested our hypothesis by culturing primary preswitched IgD + B cells from the peripheral blood of healthy subjects in the presence or absence of a crosslinking agonistic antibody to TACI (anti-TACI) and then analyzing the induction of CSR-related events by quantitative RT-PCR, flow cytometry and enzyme-linked immunosorbent assay (ELISA). IgD + B cells induced germline I γ 1-C γ 1 transcripts, an early marker of IgG1 CSR, as early as 2 d after exposure to anti-TACI ( Fig. 1b) . Switch I γ 1-C μ transcripts and AICDA transcripts encoding AID, two hallmarks of ongoing IgG1 CSR 13 , were induced by anti-TACI after 4 d ( Fig. 1c,d) . Anti-TACI alone induced some IgG2 CSR but not IgG3 or IgG4 CSR (date not shown).
We further characterized the CSR-inducing function of TACI in patients with CVID and healthy people carrying mutations in the gene encoding TACI. AICDA induction by anti-TACI was attenuated in primary IgD + B cells and lymphoblastoid B cells from patients with CVID carrying single heterozygous mutations resulting in the substitution of arginine for cysteine at position 104 (C104R) or of glutamic acid for alanine at position 181 (A181E), or with compound heterozygous mutations resulting in the C104R substitution and substitution of any amino acid for serine at position 194 (S194X), which affect the extracellular (C104R), transmembrane (A181E) or cytoplasmic (S194X) domain of TACI ( Fig. 1d,e ). C104R and A181E may affect TACI oligomerization in response to ligation of BAFF or APRIL, whereas S194X generates a truncated TACI protein lacking most of the cytoplasmic domain 26 . A heterozygous mutation resulting in substitution of alanine for valine at position 220 (V220A), which targets the cytoplasmic domain of TACI, had a less negative effect on TACI-induced AICDA expression, consistent with published studies showing that healthy people are usually heterozygous for the mutation resulting in the V220A substitution 22 . We further demonstrated the involvement of TACI in CSR in one person homozygous for a mutation that results in the substitution of any amino acid for serine at position 144 (S144X), which generates a truncated TACI protein lacking both the transmembrane and cytoplasmic domains. B cells from this patient expressed no TACI ( Fig. 1f ) and induced less AICDA and I γ 1-C μ in response to IL-4 and cognate TACI ligands such as APRIL ( Fig. 1g ) or BAFF (data not shown).
When combined with IL-10, IL-4 or IL-21, three cytokines that provide CSR-inducing cosignals 13, 14, 27 , anti-TACI increased the generation of I γ 1-C γ 1, I γ 1-C μ and AICDA transcripts more effectively than did anti-TACI alone, at least in primary B cells. Lymphoblastoid B cells showed less cooperation between anti-TACI and IL-10, probably because these cells constitutively express large amounts of endogenous IL-10. After 5 d, anti-TACI and cytokines also induced a higher frequency of B cells expressing the effector-memory antigen CD27 and class-switched IgG and IgA (Fig. 1h,i) . Finally, anti-TACI and cytokines augmented the secretion of IgG after 7 d ( Fig. 1i and Supplementary Fig. 1 ). This IgG comprised IgG1 and some IgG2, but not IgG3 or IgG4 (data not shown).
Given that TLRs induce the expression of BAFF and APRIL by cells of the innate immune response 5 , TACI may act together with TLRs to induce T cell-independent CSR. Flow cytometry showed that extrafollicular B cells had higher expression of TACI, as well as of TLR5, TLR7 and TLR9, than did follicular B cells ( Supplementary  Fig. 2 ). In addition, extrafollicular B cells showed greater upregulation of TACI expression in response to 2 d of engagement of TLR5 (by flagellin), TLR7 (by imiquimod) or TLR9 (by 2′-deoxyribo(cytidinephosphate-guanosine) (CpG DNA)), but not in response to engagement of CD40 (by CD40L; data not shown). Furthermore, CpG DNA A r t i c l e s and imiquimod (data not shown) enhanced the induction of classswitched effector B cells by anti-TACI ( Fig. 1h) . Finally, TLR ligands increased the secretion of IgG and induced the secretion of IgA in B cells exposed to anti-TACI and IL-10 ( Fig. 1i) . Thus, human TACI triggers T cell-independent pathways of IgG and IgA CSR and production by acting together with both cytokines and TLR ligands.
TACI signals CSR in cooperation with CD40
As TACI was expressed on follicular B cells, we also investigated its involvement in CD40-dependent CSR. A combination of anti-TACI and CD40L induced more class-switched CD27 + B cells and secretion of IgG than did anti-TACI or CD40L alone (Supplementary Fig. 3 ). The addition of IL-10 further increased the ability of anti-TACI to stimulate CD40-mediated production of IgG and IgA. Consistent with those findings, germinal centers from the spleen of a patient with CVID with compound heterozygous mutations resulting in the C104R and S194X TACI substitutions had lower expression of AID, whereas expression of Pax5 (a B cell-specific transcription factor) and the proliferation nuclear protein Ki67 were normal. Furthermore, patients with CVID who were heterozygous for deleterious mutations resulting in the C104R, R72H, A181E or V220A substitution, homozygous for the mutation resulting in the S144X substitution, or compound heterozygous for mutations resulting in the C104R and S194X substitutions, which affect the extracellular or intracellular domain of TACI, had a lower ratio of class-switched IgD − B cells to unswitched IgD + B cells, as did patients with hyper-IgM syndrome with deleterious substitutions of CD40L or AID ( Supplementary   Fig. 3 and Supplementary Table 1 ). Thus, human TACI mediates both T cell-independent and T cell-dependent pathways of CSR.
TACI but not CD40 interacts with MyD88
The functional cooperation of TACI with TLRs and CD40 may stem from the convergence of these receptors on both proximal and distal signaling proteins, such as TRAF6 and NF-κB, respectively 16, 24 . Given the important role of MyD88 in both T cell-independent and T cell-dependent antibody responses 23, 28, 29 , we hypothesized that TACI, TLRs and CD40 may also converge on MyD88. We generated chimeric proteins composed of glutathione S-transferase (GST) fused to the cytoplasmic domain of TACI (residues 187-293; GST-TACI) or CD40 (residues 216-277; GST-CD40) for initial precipitation and immunoblot analysis. For this we used protein extracts from 2E2, a subclone of an IgD + CL-01 human B cell line that undergoes MyD88dependent class switching in response to TLR signals 30 . Like other B cell lines, 2E2 B cells show some constitutive TACI signaling as a result of autocrine production of BAFF and APRIL 31 . We found that GST-TACI precipitated together with MyD88, whereas GST-CD40 did not ( Fig. 2a) . The interaction of GST-TACI with MyD88 was specific, as GST-TACI but not GST-CD40 was also associated with the calcium modulator and cyclophilin ligand CAML, which is a specific TACIbinding protein 32 . Furthermore, fusion proteins of GST and sequence encompassing the cytoplasmic domains of BCMA (residues 58-184) or BAFF-R (residues 100-184) associated with TRAF2, TRAF5 and TRAF6, consistent with published interaction patterns 33, 34 , but did not precipitate MyD88 or CAML ( Fig. 2a) . A r t i c l e s GST-TACI also coprecipitated MyD88 but not the TIR domaincontaining adaptor TIRAP (Mal), a TLR-associated molecule related to MyD88 (refs. 24, 35) , from total lysates of human epithelial kidney 293 cells transfected with hemagglutinin-tagged or Flag-tagged MyD88 and TIRAP expression plasmids ( Fig. 2b and Supplementary  Fig. 4 ). In addition, anti-TACI coimmunoprecipitated TACI and MyD88 from total lysates of 2E2 B cells as well as histidine-tagged TACI and MyD88 from total lysates of transfected 293 cells, whereas an isotype-matched control antibody did not ( Fig. 2c) . Coimmunoprecipitation of TACI with MyD88 probably resulted from direct physical interaction between these two proteins, because GST-TACI was also able to precipitate in vitro-translated and radiolabeled MyD88 in a cell-free system (Fig. 2d) . Thus, human TACI can interact with MyD88.
TACI recruits MyD88 after ligation
TLRs recruit MyD88 after sensing cognate microbial ligands 24 . The demonstration of ligand-induced recruitment of MyD88 to TACI in B cells is complicated by the constitutive occupation of TACI by autocrine and paracrine cognate ligands, particularly in B cell lines, and by the spontaneous oligomerization of TACI via its pre-ligand-binding assembly domain 31, 36, 37 . To circumvent those limitations, we did immunoprecipitation experiments with primary preswitched IgD + B cells from the spleens of healthy subjects. These B cells show less constitutive TACI signaling than do B cell lines and specifically generate signals from TACI in response to APRIL because they lack BCMA 37 .
In unstimulated primary IgD + B cells, some constitutive coimmunoprecipitation occurred between TACI and MyD88 but not between TACI and TRAF2 ( Fig. 2e) , perhaps due to ligandindependent aggregation of TACI through its pre-ligand-binding assembly domain 26 . Stimulation with APRIL for 15 min increased the association of TACI with MyD88 by twofold and also induced coimmunoprecipitation of TACI with TRAF2 ( Fig. 2e) . Consistent with those results, confocal microscopy showed very small plasma membrane foci of colocalized TACI and MyD88 proteins in the absence of APRIL. These scattered foci developed into large and polarized membrane patches of colocalized TACI, MyD88, TRAF2, TRAF6 and CAML after exposure to APRIL ( Fig. 2f and Supplementary Fig. 5 ). Such patches also contained flotillin-1, A r t i c l e s a protein associated with plasma membrane lipid-rich microdomains specialized in the compartmentalization of signaling molecules 38 . As TACI engagement by APRIL (or BAFF) is followed by activation of the CSR-inducing transcription factor NF-κB, we also determined whether MyD88 was required for the activation of NF-κB by TACI. Immunoblot analysis and luciferase reporter assays showed impaired MyD88 expression in I3A cells (Fig. 2g) , a subclone of 293 cells unable to respond to IL-1 (ref. 39 ). I3A cells also showed less NF-κBdependent gene transcription after overexpression of TACI for 48 h ( Fig. 2h) . Similarly, TACI induced little or no NF-κB-dependent gene transcription in 293 cells cotransfected with dominant negative MyD88 (DN-MyD88; Fig. 2i ). Of note, DN-TRAF2 and DN-TRAF6 diminished TACI-mediated NF-κB-dependent gene transcription less than DN-MyD88 did. DN-MyD88 also hampered NF-κB-dependent gene transcription in 2E2 B cells stimulated with APRIL but not in those stimulated with CD40L ( Fig. 2j) . Thus, human TACI recruits MyD88 in a ligand-dependent way to initiate downstream signaling events, including NF-κB activation.
TACI requires MyD88 to activate NF-kB
To confirm the ligand-induced recruitment of MyD88 to TACI, we stimulated resting B cells from the spleens of wildtype or MyD88-deficient C57BL/6J mice with APRIL. This ligand increased stable interactions of TACI with MyD88, TRAF2, TRAF5, TRAF6, CAML and IRAK4 as early as 5 min after B cell stimulation in wildtype mice (Fig. 3a) . After 15 min, confocal microscopy showed colocalization of TACI, MyD88 and TRAF2 in polarized cellular compartments (Fig. 3b) . Consistent with published reports showing intracellular expression of TACI 36, 37 , APRIL triggered cytoplasm-to-membrane translocation of not only MyD88 and TRAF2 but also some TACI. We then assessed by immunoblot analysis the role of MyD88 in early NF-κB signals emanating from TACI. APRIL induced phosphorylation of IKKα, IKKβ and IκBα (triggering its degradation; data not shown) as early as 5 min in wild-type cells, whereas no phosphorylation occurred in MyD88-deficient B cells (Fig. 3c) . Phosphorylation of p38, a mitogen-activated kinase signal transducer associated with many receptors, including TLRs 24 , was not induced by APRIL.
We assessed nuclear extracts obtained from wild-type or MyD88-deficient B cells left unstimulated or stimulated for 3 h with APRIL or BAFF by electrophoretic mobilityshift assay using a probe derived from κB2, a key NF-κB-binding κB site from the I γ 1 promoter 3 . Wild-type B cells induced nuclear translocation of C1 and C2 complexes containing the NF-κB subunits p50, p65 and c-Rel after exposure to BAFF or APRIL, whereas MyD88-deficient B cells did not (Fig. 3d) . In MyD88-deficient mice, κB2 was associated with a distinct C3 complex that lacked p50, p65 and c-Rel in both unstimulated and stimulated B cells (Supplementary Fig. 6 ). In mice, optimal transcription of C γ 1 and C ε , a gene functionally related to C γ 1, requires a second signal provided by IL-4 (ref. 3) . Stimulation with a combination of APRIL and IL-4 induced more robust expression of germline I γ 1-C γ 1 and I ε -C ε transcripts than did stimulation with 
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A r t i c l e s APRIL or IL-4 alone, as early as 6 h after stimulation, as detected by quantitative RT-PCR ( Fig. 3e and Supplementary Fig. 7) . This early induction of transcription did not occur in the absence of MyD88. Thus, TACI requires MyD88 for the early initiation of NF-κB-dependent germline C H gene transcription.
TACI signals through a TIR-less MyD88-binding site
We then investigated the molecular requirements for the interaction of human TACI with MyD88. Comparison of the cytoplasmic domain of TACI from various species led to the identification of five highly conserved domains with a high hydrophobicity index ( Supplementary  Fig. 8 ), which has been linked to protein-protein interactions. These conserved regions included the sequence Pro-Thr-Gln-Glu-Ser, which is a canonical TRAF2-binding site. Given that TRAF2 is critical for the induction of CSR by CD40 (ref. 34) , we used this sequence as a reference to generate progressive deletion mutants of TACI, which we subsequently used in precipitation assays to map the MyD88-binding site of TACI (Fig. 4a) . GST-TACI interacted with MyD88 through a cytoplasmic region spanning amino acids 217-239 that we called the 'TACI highly conserved' (THC) domain (Fig. 4b) . This THC domain was upstream of the TRAF2-binding site and lacked any similarity with TIR. Additional assays further narrowed the MyD88-binding site to a highly conserved segment of the THC domain spanning amino acids 228-239. Of note, TRAF5, TRAF6 and CAML, but not MyD88 or TRAF2, showed conserved binding to constructs encompassing the transmembrane domain or, eventually, a fragment of the cytoplasmic region of TACI. Protein sequence analysis led to the identification of two transmembrane domains and a TRAF-binding site in CAML (Supplementary Fig. 9 ). In addition, CAML immunoprecipitated together with TRAF5 and TRAF6 from 2E2 B cells with constitutive TACI signaling activity, which suggested that TACI amplifies the recruitment of TRAF5 and TRAF6 by interacting with CAML through one or both its transmembrane domains.
Luciferase reporter assays showed that a TACI deletion mutant lacking only the TRAF2-binding site induced NF-κB and AP-1, a transcription factor involved in B cell activation but not CSR, less effectively than did wild-type TACI (Fig. 4c) . Another TACI deletion mutant lacking both the TRAF2-binding site and the THC domain showed almost no induction of NF-κB and AP-1 despite retaining TRAF5-, TRAF6-and CAML-binding activity. We investigated the contributions of MyD88 and TRAF2 to TACI signaling further by using site-directed mutagenesis to generate E228R, T229R, S231R and C233G substitutions affecting the THC domain but not the TRAF2-binding motif of TACI (Fig. 4d) . These substitutions decreased the binding of MyD88, but not of TRAF2, TRAF5, TRAF6 or CAML, to TACI ( Fig. 4e) and attenuated TACI signaling via both NF-κB and AP-1 (Fig. 4f) .
A control A181E substitution affecting the transmembrane domain of TACI or R202H, P219A, V220A and P226A substitutions affecting the cytoplasmic domain of TACI outside its MyD88-, TRAF-and CAML-binding sites had little or no inhibitory effect on TACI signaling via NF-κB and AP-1 and did not impair the interaction of TACI with MyD88, TRAF2, TRAF5, TRAF6 or CAML ( Fig. 4f and  Supplementary Fig. 10 ). An additional S194X substitution truncating the cytoplasmic tail of TACI upstream of the MyD88-and TRAF2binding sites had no effect on the interaction of TACI with TRAF5, TRAF6 and CAML but abolished the binding of TACI to MyD88 and TRAF2 and the signaling by TACI via NF-κB and AP-1. Thus, TACI recruits MyD88 and activates NF-κB via a TIR-less THC domain.
TACI interacts with MyD88 in a TIR-independent way
MyD88 dimerization occurs after TLR stimulation, which facilitates interaction of the death domain of MyD88 with a homologous death domain of IRAK1 and IRAK4 (Fig. 5a) . By recruiting TRAF6, IRAK4 mediates activation of the kinase TAK1, which in turn activates IKK 24 . Consistent with the lack of TIR in the cytoplasmic tail of TACI, Flag-tagged MyD88 proteins encompassing amino acids 1-260 or 1-160 and lacking all or part of the TIR domain retained the ability to interact with GST-TACI and had little or no dominant negative effect on TACI signaling via NF-κB and AP-1 in 293 cells (Fig. 5b,c) . A Flag-tagged MyD88 protein encompassing amino acids 1-109 and lacking both the TIR domain and the intermediary region showed no binding to GST-TACI; instead, this construct showed potent inhibitory activity against TACI signaling via both NF-κB and AP-1. We observed a similar dominant negative effect with a T T M  H  C  D  1 H  C  D  2  H  C  D  3  H  C  D  4  H  C  D  5  (kDa)  30  50   60  60   60   30   W   T  D  1  D  2  D  3  D  4  D  5  D  6  D  7  I P : G   S T   IB: TRAF2  IB: TRAF5  IB: TRAF6  IB: CAML  IB: Fig. 11) . Supplementary Fig. 13 ). PCR1 and PCR2 indicate independent PCR amplifications; bp, base pairs. Data are representative of three (a), four (b) or two (c) experiments. position 93 and of cysteine for arginine at position 196 ( Fig. 5d) , which mimic those that cause MyD88 deficiency and are found in patients with an immunodeficiency causing recurrent infections in childhood 40 .
As TACI recruits IRAK4 and TRAF6 in addition to MyD88, we determined the role of those and other TLR-associated signal transducers in the activation of NF-κB by TACI. Precipitation assays showed that human GST-TACI bound IRAK1 and IRAK4 from 2E2 B cells (Fig. 5e) , whereas luciferase reporter assays demonstrated that dominant negative versions of IRAK1, IRAK4, TRAF6, TAK1, IKKα and IKKβ inhibited induction of NF-κB by TACI in 293 cells (Fig. 5f) . Also DN-TRAF2 had an inhibitory effect on TACI-induced NF-κB activation, but this was less than the effect of DN-MyD88. A similar dominant negative approach confirmed the involvement of IRAK1, IRAK4, TRAF6, TAK1 and IKKβ, but not of TRAF3, in the induction of NF-κB by BAFF in 2E2 B cells (Supplementary Fig. 12 ). Thus, MyD88 does not make use of the TIR-TIR interaction to bind to TACI, yet signals through a TLR-like pathway emanating from TACI and cooperating with TRAF2.
TACI requires MyD88 to trigger CSR We next sought to determine whether the lack of MyD88 or IRAK4 attenuates IgG CSR in humans. Despite having conserved serum IgG, some MyD88-and IRAK4-deficient patients had impaired IgG responses to microbial polysaccharide 41 (Supplementary Table 1) , a canonical T cell-independent antigen. Similar to people with TACI defects, these patients also had a lower ratio of IgD − B cells to IgD + B cells than did age-matched healthy controls and patients with unrelated inflammatory disorders (Fig. 6a) . B cells from two MyD88-deficient patients and three IRAK4-deficient patients induced AICDA transcripts less strongly after 4 d of exposure to BAFF, APRIL or CpG DNA than did B cells from healthy subjects (Fig. 6b) . AICDA induction by BAFF and/or APRIL was blunted in two IRAK4-deficient patients with a normal ratio of IgD − B cells to IgD + B cells, whereas one MyD88-deficient patient showed a paradoxically stronger response to BAFF, APRIL and CpG DNA (Supplementary Fig. 13 ). Finally, B cells from a MyD88-deficient patient expressed fewer I γ 1-C γ 1, I γ 2-C γ 2 and I γ 1-C μ transcripts after 4 d of exposure to monocytes expressing BAFF and APRIL than did B cells from a healthy control ( Fig. 6c and Supplementary Fig. 14) .
As the MyD88-binding site was identical in human and mouse TACI proteins (Fig. 7a) , we sought to confirm in mouse B cells whether MyD88 was required for the induction of CSR by TACI. Naive B cells from the spleen of MyD88-deficient mice induced fewer I γ 1-C γ 1, AICDA and I γ 1-C μ transcripts and secreted less IgG1 after 2, 4 or 7 d of exposure to BAFF, APRIL or CpG DNA and IL-4 than did control B cells (Fig. 7b,c) . The lack of MyD88 also impaired the induction of I α -C μ and membrane IgA by APRIL and IL-4 ( Fig. 7d ) and the induction of AICDA and I γ 1-C γ 1 by anti-TACI (Fig. 7e) . These effects were specific, as the lack of MyD88 did not hamper the IgM secretion and minimally affected the survival of B cells exposed to BAFF or APRIL (Supplementary Fig. 15 ). Thus, MyD88 regulates CSR via a TIR-independent pathway emanating from TACI (Supplementary Fig. 16 ).
DISCUSSION
Here we have shown that BAFF and APRIL elicited CSR by inducing recruitment of MyD88 to a highly conserved THC cytoplasmic domain of TACI different from the TIR domain of TLRs. Interaction of TACI with MyD88 initiated germline C H gene transcription, AID expression and CSR by activating NF-κB through a TLR-like signaling cascade that was impaired in mice and humans lacking MyD88 or IRAK4. These findings indicate that MyD88 controls a previously unknown B cell-intrinsic, TACI-dependent, TIR-independent pathway for immunoglobulin gene diversification and production.
TLR signaling is commonly visualized as a linear cascade initiated by recruitment of MyD88 to the TIR domain 24 , yet TLRs generate convoluted signaling routes characterized by extensive branching and crosstalk with non-TLR pathways 42 A r t i c l e s recruitment of MyD88 to TACI, our findings point to the existence of intimate B cell-intrinsic crosstalk between TACI and TLRs and provide a new molecular framework for observations indicating that BAFF and APRIL need MyD88 to generate IgG and IgA 23, 29, 43 . Unlike TLRs, TACI did not make use of the TIR domain to interact with MyD88 but instead relied on a highly conserved THC domain. This motif recognized the intermediary region domain of MyD88, which is also required by MyD88 for interaction with the interferon-γ receptor 44 .
Similar to TLRs, TACI used a MyD88-IRAK1-IRAK4-TRAF6-TAK1-IKK signaling pathway to activate NF-κB in B cells. TACI-induced NF-κB initiated germline C γ 1 gene transcription by transactivating the I γ 1 promoter after binding to key cis-regulatory sites such as κB2. In MyD88-deficient B cells, this κB2 site was constitutively occupied by unknown proteins possibly corresponding to transcriptional repressors, which suggests that MyD88 exerts a complex control on CSR. A similar MyD88-dependent pathway probably supported TACI-induced AICDA transcription, because lack of MyD88 or IRAK4 impaired AICDA induction in response to TACI ligation. In general, TACI required cosignals from IL-4, IL-10 or IL-21 to elicit optimal C H and AICDA transcription and subsequent CSR. Additional cosignals from TLRs were needed to initiate production of IgG and IgA.
A prominent feature of the MyD88-binding site of TACI was its proximity to a canonical TRAF2-binding site. Deletion of both MyD88and TRAF2-binding sites abrogated TACI signaling, whereas disruption of either site did not, which suggests that MyD88 and TRAF2 function in a cooperative manner. Such cooperation may be fostered by the ability of TACI of eliciting ligand-dependent colocalization of MyD88 and TRAF2 in flotillin-1-containing plasma membrane microdomains specialized in the organization of signaling complexes 38 . Flotillin-1-containing areas also contained TRAF6 and CAML. The contribution of TRAF6 to TACI signaling is unclear, but it may function downstream of MyD88 to facilitate the activation of IKK. TRAF6 also interacted with CAML, a transcription factor NFAT-inducing protein that binds to the membrane-proximal cytoplasmic domain of TACI 32, 45 . Although it is able to also interact with TRAF5, CAML eventually had a marginal role in inducing the activation of NF-κB and AP-1 by TACI, which mostly required MyD88 and TRAF2. However, TACI may use CAML to enhance B cell proliferation, B cell survival and plasmacytoid differentiation independently of NF-κB and AP-1, perhaps through a pathway involving NFAT 46, 47 .
In agreement with published data 15, 17, 40, 41, 43, 48 , TACI signaling via MyD88 and MyD88-interacting proteins such as IRAK4 may help extrafollicular B cells to mount sustained IgG and IgA responses to T cell-independent antigens such as polysaccharides from encapsulated bacteria. Consistent with that interpretation, some patients with MyD88 or IRAK4 deficiency showed lower IgG responses to pneumococcal polysaccharides in addition to impaired induction of AID and IgG CSR in B cells exposed to BAFF or APRIL. As suggested by published findings 47 , the TACI-MyD88 interaction may further enhance T cell-independent antibody responses by delivering survival signals to activated extrafollicular B cells, including class-switched plasmablasts.
TACI signaling via MyD88 may also enhance IgG and IgA responses to T cell-dependent antigens such as common microbial proteins. Accordingly, follicular B cells expressed TACI and augmented IgG production after dual engagement of TACI and CD40. Moreover, patients with deleterious TACI substitutions had lower AID expression in the germinal center, a B cell area highly dependent on CD40. The involvement of TACI signaling via MyD88 in T cell-dependent humoral immunity would be consistent with the impairment of T celldependent IgG responses in mice with a B cell-intrinsic deficiency in MyD88, at least in some models 28, 49, 50 . Despite their involvement in TACI-induced CSR, MyD88 and its downstream partner IRAK4 were not critical for the control of circulating IgG and IgA under steadystate conditions. This could be explained by the fact that TACI uses TRAF2 to compensate for the lack of MyD88 or IRAK4. Further compensatory signals may be generated by BAFF-R, BCMA and CD40, which indeed did not make use of MyD88.
Published data have shown that lupus-prone T cell-deficient mice require MyD88 to develop IgG autoantibodies in response to a BAFF transgene 23 , which suggests that TACI signaling via MyD88 may exacerbate autoimmunity by promoting IgG CSR in autoreactive B cells. Should this be the case, small inhibitors of the TACI-MyD88 interaction could be used to treat autoimmune disorders associated with pathogenic CSR and dysregulated expression of BAFF and APRIL. A more general implication of our findings is that MyD88 has important adaptive functions, given its use downstream of TACI by B cells, and therefore cannot be regarded as an adaptor molecule that operates exclusively in the innate immune system. By conveying CSR-inducing signals emanating from both TACI and TLRs, MyD88 probably serves as a B cell-intrinsic molecular bridge between innate and adaptive responses. Consequently, the B cell-related phenotypes observed before in MyD88-deficient mice 28, 29, 50 may not result solely from defective TLR and IL-1R signaling but instead probably involve additional defects in TACI signaling.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
